Placebo-controlled randomized clinical trial testing the efficacy and safety of varenicline for smokers with HIV.

ABSTRACT:

Background

People living with HIV/AIDS (PLWH) smoke tobacco at higher rates and have more difficulty quitting than the general population, which contributes to significant life-years lost. The effectiveness of varenicline, one of the most effective tobacco dependence treatments, is understudied in HIV. We evaluated the safety and efficacy of varenicline for smoking cessation among PLWH.

Methods

This was a single-site randomized, double-blind, placebo-controlled, phase 3 clinical trial (NCT01710137). PLWH on antiretroviral therapy (ART) who were treatment-seeking daily smokers were randomized (1:1) to 12 weeks of varenicline (n = 89) or placebo (n = 90). All participants were offered six smoking cessation behavioral counseling sessions. The primary outcome was 7-day point pre

SUBMITTER: Ashare RL 

PROVIDER: S-EPMC6588414 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature